report wait ration market
ci report ep top street consensu
adjust result exclud gain transit client
invest off-set amort integration/transact cost
beat driven strong result integr medic vs opco
slightli off-set group soft vs opco meanwhil
new servic segment move part line
manag estim due organ sale growth follow quarter cigna
rais ep guidanc result
rais ep estim
esrx deal perform posit esrx busi
show y-i growth though number move part limit compar
esrx histor number manag discuss grown pharmaci
custom organ due strong new commerci sale
retent rate sell season expect
strong leverag come gener ocf
vs prior period compani deploy cash toward de-lever
share repurchas continu expect reduc
debt-to-cap current level high end
disabl busi face blip rebound group miss
estim vs opco due unfavor disabl claim howev
compani qualifi result weak januari return
normal february/march segment account pre-tax
estim appear concern go forward
driven improv integr medic
earn compani also expect ep
full-year earn impli reiter
ep project
conclus overal strong result momentum pharmaci segment
encourag way start year given strong track record attract
valuat compel growth opportun maintain outperform rate
would buyer current price
year price histori ci
provid health care relat
benefit us intern
compani offer insur self-
health vision plan well
disabl life insur product
analyst certif import disclosur see disclosur
integr includ express script goe
portfolio target strong growth market avoid
mani risk driven concentr aso
busi compani also strong track record growth
recent year tradit trade discount
peer although posit neg
express script deal believ highli accret deal
pay strong long-term return sharehold given compel
opportun cross-sel servic mention
equity-friendli capit structur result rate stock
guidanc issu updat
integr includ express script goe well
medicar busi growth margin acceler
signific uptick util
integr includ express script goe poorli
disabl life busi continu face volatil
exchang busi turn materi loss
price target base combin two methodolog dcf valuat base beta
termin growth rate wacc estim ebitda price-to-earnings target repres
ep estim conserv discount group current trade compani face
integr risk express script transact uncertain drug regulatori environ
includ healthcar reform federal/st regul chang cost trend intern busi risk
oppenheim co inc compani report
premium fee
healthcar premium
sell gener administr expens
premium fee
pharmaci servic cost elimin
total benefit expens
incom attribut non-controlling interest
dilut ep report
premium fee
sell gener administr expens
total benefit expens
